SetPoint Medical Company
SetPoint Medical is dedicated to treating patients with debilitating inflammatory diseases, such as Crohn's Disease and rheumatoid arthritis, using proprietary implantable bioelectronic devices. The company developing novel bioelectronic medicine therapies to treat those who suffer from autoimmune diseases such as rheumatoid arthritis, Crohn's Disease, and multiple sclerosis. The scientific platform is based on the Inflammatory Reflex—the natural mechanism by which the central nervous system regulates the immune system. This mechanism was discovered by SetPoint co-founder Kevin Tracey and published in Nature in May 2000. Since then, the Inflammatory Reflex has been characterized in more than 100 peer reviewed papers in leading scientific journals. Anti-inflammatory potency comparable to leading drugs has been demonstrated in multiple animal models. The company is currently conducting human trials in rheumatoid arthritis at four European centers. SetPoint's microregulator is intended to supplement the body's natural Inflammatory Reflex by providing 'built-in' therapy at a lower cost and with improved safety compared with drugs or biologic solutions.